APA (7th ed.) Citation

Crawford, S., Li, H., Srivastava, B., Martin, P., Gahn, J., & Rogers, K. (2024). EE91 Clinical Consequences and Associated Costs of Treating Patients With Chronic Lymphocytic Leukemia (CLL) With Bruton Tyrosine Kinase Inhibitors (BTKis) in the First-Line (1L) and Relapsed/Refractory (R/R) Settings. Value in Health, 27(6), S74. https://doi.org/10.1016/j.jval.2024.03.391

Chicago Style (17th ed.) Citation

Crawford, S., H. Li, B. Srivastava, P. Martin, J. Gahn, and KA Rogers. "EE91 Clinical Consequences and Associated Costs of Treating Patients With Chronic Lymphocytic Leukemia (CLL) With Bruton Tyrosine Kinase Inhibitors (BTKis) in the First-Line (1L) and Relapsed/Refractory (R/R) Settings." Value in Health 27, no. 6 (2024): S74. https://doi.org/10.1016/j.jval.2024.03.391.

MLA (9th ed.) Citation

Crawford, S., et al. "EE91 Clinical Consequences and Associated Costs of Treating Patients With Chronic Lymphocytic Leukemia (CLL) With Bruton Tyrosine Kinase Inhibitors (BTKis) in the First-Line (1L) and Relapsed/Refractory (R/R) Settings." Value in Health, vol. 27, no. 6, 2024, p. S74, https://doi.org/10.1016/j.jval.2024.03.391.